Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eczema drug tralokinumab under eye scrutiny: new study tracks conjunctivitis risk

NCT ID NCT05682976

First seen May 10, 2026 · Last updated May 21, 2026 · Updated 2 times

Summary

This study looked at eye problems in 100 adults with atopic dermatitis (eczema) who were treated with tralokinumab. The main goal was to find out how often eye issues like conjunctivitis happen within the first 4 months of treatment. Researchers hope this will help doctors better manage and prevent these side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHRU de Lille

    Lille, France

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Brest

    Brest, France

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • CHU de Nantes

    Nantes, France

  • CHU de Rouen

    Rouen, France

  • CHu de Dijon

    Dijon, France

  • CHu de Poitiers

    Poitiers, France

  • CHu de Rennes

    Rennes, France

  • Hospice Civil de Lyon

    Lyon, France

  • Hôpital Saint Louis

    Paris, France

Conditions

Explore the condition pages connected to this study.